Olympus Corp 2025 IR
The report outlines Olympus' strategic progress and financial performance for the fiscal year ended March 31, 2025, highlighting its transition into a pure MedTech company. Key achievements include a 62% reduction in Scope 1 and 2 greenhouse gas emissions compared to FY2020 and the successful implementation of the quality and regulatory transformation project, Elevate. The company also expanded its clinical training programs, delivering 57 colorectal cancer-related training programs in target emerging countries. Additionally, Olympus advanced its digital health strategy with the development of the OLYSENSE cloud-based endoscopy ecosystem and prepared for local production in China to drive future growth.
Company: Olympus Corp
Sector: Health Care
Country: Japan
Year: 2025
Type: IR
Pages: 306
Olympus Corp
Annual Securities Report
The report outlines Olympus' strategic progress and financial performance for the fiscal year ended March 31, 2025, highlighting its transition into a pure MedTech company. Key achievements include a 62% reduction in Scope 1 and 2 greenhouse gas emissions compared to FY2020 and the successful implementation of the quality and regulatory transformation project, Elevate. The company also expanded its clinical training programs, delivering 57 colorectal cancer-related training programs in target emerging countries. Additionally, Olympus advanced its digital health strategy with the development of the OLYSENSE cloud-based endoscopy ecosystem and prepared for local production in China to drive future growth.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2025
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Renewable Energy
Women on Board
Women in Management
Net Zero Target
Employees